ATE190614T1 - Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung - Google Patents

Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung

Info

Publication number
ATE190614T1
ATE190614T1 AT94120539T AT94120539T ATE190614T1 AT E190614 T1 ATE190614 T1 AT E190614T1 AT 94120539 T AT94120539 T AT 94120539T AT 94120539 T AT94120539 T AT 94120539T AT E190614 T1 ATE190614 T1 AT E190614T1
Authority
AT
Austria
Prior art keywords
dihydrate
hydrochloride
dimethoxychinazol
tetrahydrofuroyl
amino
Prior art date
Application number
AT94120539T
Other languages
English (en)
Inventor
Regis Borrega
Satoshi Kitamura
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE190614T1 publication Critical patent/ATE190614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94120539T 1993-12-28 1994-12-23 Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung ATE190614T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5353828A JPH07206857A (ja) 1993-12-28 1993-12-28 アルフゾシン塩酸塩の二水和物

Publications (1)

Publication Number Publication Date
ATE190614T1 true ATE190614T1 (de) 2000-04-15

Family

ID=18433498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94120539T ATE190614T1 (de) 1993-12-28 1994-12-23 Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung

Country Status (6)

Country Link
US (1) US5545738A (de)
EP (1) EP0663398B1 (de)
JP (1) JPH07206857A (de)
KR (1) KR100329156B1 (de)
AT (1) ATE190614T1 (de)
DE (1) DE69423459T2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
PL1789412T3 (pl) * 2004-09-16 2008-10-31 Hetero Drugs Ltd Krystaliczna zasada alfuzosyny
US20070049756A1 (en) * 2005-08-30 2007-03-01 Anumula Raghupathi R Alfuzosin hydrochloride polymorphs
WO2007069050A2 (en) * 2005-12-16 2007-06-21 Wockhardt Ltd. Processes for the preparation of alfuzosin
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
WO2008114272A2 (en) * 2007-03-22 2008-09-25 Cadila Healthcare Limited Process for preparing alpuzosin and crystalline alfuzosin hydrochloride
EP2152697A2 (de) 2007-05-04 2010-02-17 Actavis Group PTC EHF Verfahren zur herstellung von alfuzosin und salzen daraus
KR20100044239A (ko) * 2007-08-02 2010-04-29 시플라 리미티드 알푸조신 염산염의 제조방법
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN114674967B (zh) * 2022-03-25 2022-10-04 邦恩泰(山东)生物医药科技集团股份有限公司 N-甲基-n′-四氢呋喃甲酰基丙二胺草酸盐有关物质的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition

Also Published As

Publication number Publication date
JPH07206857A (ja) 1995-08-08
EP0663398A1 (de) 1995-07-19
KR100329156B1 (ko) 2002-11-22
US5545738A (en) 1996-08-13
DE69423459T2 (de) 2000-10-26
EP0663398B1 (de) 2000-03-15
KR950017992A (ko) 1995-07-22
DE69423459D1 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
ATE190614T1 (de) Dihydrat des n-(4-amino-6,7-dimethoxychinazol-2- yl)-n-methyl-n'-(tetrahydrofuroyl-2)- propylendiamin hydrochlorids(=alfuzosin hydrochlorid dihydrat) und ein verfahren zur herstellung
ATE410412T1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
ATE220667T1 (de) Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
NO905172D0 (no) Aminokarbonylkarbamater beslektet med fysostigmin og fremgangsmaate for fremstilling derav.
DE69319296D1 (de) Verfahren zur Reinigung von roher Clavulansäure
ATE194976T1 (de) Verfahren zur herstellung von n-(amidinophenyl pyrrolidin)-n'-beta-alanin-substituierten harnstoffen
ATE100077T1 (de) 2-hydroxy-3-phenoxypropylaminoverbindungen.
BR9707004A (pt) Composto processo para preparar o mesmo composição farmacêutica utilização do composto e processos para tratamento de doenças do sistema endocinológico e para a manufatura de um medicamento
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
DE59009951D1 (de) Verfahren zur Herstellung von Zwischenprodukten und zur Synthese von N-(2-Hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxypiperidine.
ATE207482T1 (de) Verfahren zur herstellung von n2-arylsulfonyl-l- argininamiden
DE69107561T2 (de) Verfahren zur Herstellung von 4-Methylsulfonylbenzoesäurederivate und Zwischenprodukte.
DE69127960T2 (de) Verfahren zur Herstellung von (S)-vinyl- und (S)-allenyl-Gaba
DE69229017T2 (de) Glyceraldehyd-3-pentanid und Verfahren zu ihrer Herstellung
ATE157655T1 (de) Verfahren zur herstellung von gegebenfalls 2- substituierten 5-chlorimidazolen
FI924769A0 (fi) Foerfarande foer framstaellning av substituerade indoler
ATE169908T1 (de) Verfahren zur herstellung von gegebenenfalls 2- substituierten 5-chlorimidazol-4-carbaldehyden
ATE164573T1 (de) Verfahren zur herstellung von 1-unsubstituierten 3-aminopyrrolen
ATE229495T1 (de) Verfahren zur herstellung von n-acyl- aminosäureestern und n-acyl-aminoacetalen
DE3785963T2 (de) Dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE9219T1 (de) N-(2-(2-amino-2-phenylethyl)phenyl)-2,2dimethylpropanamid und derivate und ein verfahren zur herstellung derselben.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties